ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Advisors OK Levamisole, Conditional New Tamoxifen Use

February 9, 1990

FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”

September 3, 1976

Possible Government Shutdown Looms Over Biomedical Research Funding Once More

September 23, 2011

DCCR Free Up $5 Million; New Policy Limits Core Support

November 5, 1976

Saul Rivin Receives ACCC Clinical Research Award.

December 1, 2000

Did ACS Flip-Flop On Stem Cell Research? Society Says No, Patient Coalition Says Yes

September 10, 1999